TY - JOUR T1 - Bayesian Inference of State-Level COVID-19 Basic Reproduction Numbers across the United States JF - medRxiv DO - 10.1101/2021.09.27.21264188 SP - 2021.09.27.21264188 AU - Abhishek Mallela AU - Jacob Neumann AU - Ely F. Miller AU - Ye Chen AU - Richard G. Posner AU - Yen Ting Lin AU - William S. Hlavacek Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/28/2021.09.27.21264188.abstract N2 - Although many persons in the United States have acquired immunity to COVID-19, either through vaccination or infection with SARS-CoV-2, COVID-19 will pose an ongoing threat to non-immune persons so long as disease transmission continues. We can estimate when sustained disease transmission will end in a population by calculating the population-specific basic reproduction number ℛ0, the expected number of secondary cases generated by an infected person in the absence of any interventions. The value of ℛ0 relates to a herd immunity threshold (HIT), which is given by 1 − 1/ℛ0. When the immune fraction of a population exceeds this threshold, sustained disease transmission becomes exponentially unlikely (barring mutations allowing SARS-CoV-2 to escape immunity). Here, we report state-level ℛ0 estimates obtained using Bayesian inference. Maximum a posteriori estimates range from 7.1 for New Jersey to 2.3 for Wyoming, indicating that disease transmission varies considerably across states and that reaching herd immunity will be more difficult in some states than others. ℛ0 estimates were obtained from compartmental models via the next-generation matrix approach after each model was parameterized using regional daily confirmed case reports of COVID-19 from 21-January-2020 to 21-June-2020. Our ℛ0 estimates characterize infectiousness of ancestral strains, but they can be used to determine HITs for a distinct, currently dominant circulating strain, such as SARS-CoV-2 variant Delta (lineage B.1.617.2), if the relative infectiousness of the strain can be ascertained. On the basis of Delta-adjusted HITs, vaccination data, and seroprevalence survey data, we find that no state has achieved herd immunity as of 20-September-2021.Significance Statement COVID-19 will continue to threaten non-immune persons in the presence of ongoing disease transmission. We can estimate when sustained disease transmission will end by calculating the population-specific basic reproduction number ℛ0, which relates to a herd immunity threshold (HIT), given by 1 − 1/ℛ0. When the immune fraction of a population exceeds this threshold, sustained disease transmission becomes exponentially unlikely. Here, we report state-level ℛ0 estimates indicating that disease transmission varies considerably across states. Our ℛ0 estimates can also be used to determine HITs for the Delta variant of COVID-19. On the basis of Delta-adjusted HITs, vaccination data, and serological survey results, we find that no state has yet achieved herd immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge support from the 2020 Mathematical Sciences Graduate Internship program sponsored by the Division of Mathematical Sciences of the National Science Foundation. We acknowledge support from NIH/NIGMS grant R01GM111510. We acknowledge support from the Laboratory Directed Research and Development (LDRD) program at Los Alamos National Laboratory. We are grateful to access to the FARM cluster at University of California, Davis and the Monsoon cluster at Northern Arizona University which is supported by the Arizona Technology and Research Initiative Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInferences were obtained using problem-specific code. The functionality of the code has been added to a freely available open-source software package (PyBioNetFit, version 1.1.9). We have confirmed that the results of the problem-specific code are reproduced by PyBioNetFit. https://github.com/lanl/PyBNF ER -